Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IMVTthis companyImmunovant, Inc.	$33.48	-8.97×	5.31×	0×	-7.19×	-83.0%	0.0%	0.0%	0.0%	-59.3%	-62.5%	-9.0%	0×	1.79×	0×	9.09×	0.0%	3	26.71	1	D+
ACRSAclaris Therapeutics, Inc.	$3.95	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ANABAnaptysBio, Inc.	$46.78	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ANNXAnnexon, Inc.	$4.24	-3.75×	3.68×	0×	-3.14×	-80.0%	0.0%	0.0%	0.0%	-97.7%	-91.0%	-24.0%	0.12×	0.66×	0×	5.68×	0.0%	1	-1.2	2	C
CABACabaletta Bio, Inc.	$1.39	-1.34×	2×	0×	-1.02×	-65.7%	0.0%	0.0%	0.0%	-149.8%	-123.8%	-59.1%	0.24×	0.34×	-85.95×	2.77×	0.0%	2	-1.41	2	C+
CGEMCullinan Therapeutics, Inc.	$11.10	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
Peer median	—	-3.75×	3.58×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-63.0%	-58.7%	-24.0%	0.12×	0.34×	0×	5.68×	0.0%	2	-1.2	2	—